3VA1
 
 | | Crystal structure of the mammalian MDC1 FHA domain | | Descriptor: | Mediator of DNA damage checkpoint protein 1, SULFATE ION | | Authors: | Wu, H.H, Wu, P.Y, Huang, K.F, Kao, Y.Y, Tsai, M.D. | | Deposit date: | 2011-12-28 | | Release date: | 2012-02-01 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (1.74 Å) | | Cite: | Structural Delineation of MDC1-FHA Domain Binding with CHK2-pThr68.
Biochemistry, 2012
|
|
3VA4
 | | Crystal structure of the mammalian MDC1 FHA domain complexed with CHK2 pThr68 peptide | | Descriptor: | Mediator of DNA damage checkpoint protein 1, Serine/threonine-protein kinase Chk2 | | Authors: | Wu, H.H, Wu, P.Y, Huang, K.F, Kao, Y.Y, Tsai, M.D. | | Deposit date: | 2011-12-28 | | Release date: | 2012-02-01 | | Method: | X-RAY DIFFRACTION (1.54 Å) | | Cite: | Structural Delineation of MDC1-FHA Domain Binding with CHK2-pThr68.
Biochemistry, 2012
|
|
3II6
 | |
7F62
 | | Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region) | | Descriptor: | RBD-chAb-25, Heavy chain, Light chain, ... | | Authors: | Yang, T.J, Yu, P.Y, Wu, H.C, Hsu, S.T.D. | | Deposit date: | 2021-06-24 | | Release date: | 2021-08-04 | | Last modified: | 2022-02-16 | | Method: | ELECTRON MICROSCOPY (3.6 Å) | | Cite: | Structure-guided antibody cocktail for prevention and treatment of COVID-19.
Plos Pathog., 17, 2021
|
|
7F63
 | | Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refinement of S-RBD and chAb-45 region) | | Descriptor: | RBD-chAb45, Heavy chain, Light chain, ... | | Authors: | Yang, T.J, Yu, P.Y, Wu, H.C, Hsu, S.T.D. | | Deposit date: | 2021-06-24 | | Release date: | 2021-08-04 | | Last modified: | 2022-02-16 | | Method: | ELECTRON MICROSCOPY (3.9 Å) | | Cite: | Structure-guided antibody cocktail for prevention and treatment of COVID-19.
Plos Pathog., 17, 2021
|
|
4GH6
 | | Crystal structure of the PDE9A catalytic domain in complex with inhibitor 28 | | Descriptor: | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, MAGNESIUM ION, N-(4-methoxyphenyl)-N~2~-[1-(2-methylphenyl)-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-L-alaninamide, ... | | Authors: | Hou, J, Ke, H. | | Deposit date: | 2012-08-07 | | Release date: | 2012-10-03 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design.
J.Med.Chem., 55, 2012
|
|
